Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Tricine-SDS-PAGE Gel Preparation Kit Guide
2026-08-14
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed for resolving low-molecular-weight proteins and peptides, particularly targets in the 1–10 kDa range. It supports research workflows involving denaturing or non-denaturing electrophoresis, but it is not intended for diagnostic, clinical, or medical use.
-
SGI-1027: DNA Methyltransferase Inhibition
2026-08-13
SGI-1027 is a non-nucleoside DNA methyltransferase inhibitor for connecting DNMT blockade with promoter demethylation, tumor suppressor gene reactivation, and apoptosis readouts. This workflow-focused guide covers assay design, handling, comparative advantages, and troubleshooting for cancer epigenetics research.
-
3-Deazaneplanocin (DZNep) Workflow Guide
2026-08-13
Build reproducible DZNep experiments around SAHH inhibition, EZH2 depletion, apoptosis, and tumor-initiating cell assays. This guide connects AML, hepatocellular carcinoma, and breast cancer workflow design while emphasizing dose selection, phenotype-specific controls, and troubleshooting.
-
Concanamycin A: A Trafficking-Centered Assay Guide
2026-08-12
Concanamycin A is a V-type H+-ATPase inhibitor that reveals how organelle acidification shapes autophagy, trafficking, apoptosis, and tumor-cell invasion. This guide connects the compound’s acute pharmacology with a recent ER-exit-site study to improve mechanistic assay design.
-
GW 4869 (hydrochloride hydrate) Lab Guide
2026-08-12
This scenario-based guide explains how GW 4869 (hydrochloride hydrate), SKU C4769, can improve mechanistic studies of neutral sphingomyelinase, ceramide signaling, and extracellular vesicle release. It covers assay compatibility, DMSO handling, viability controls, interpretation, and practical product-selection criteria.
-
HSP90 Regulation of RNA Foci in DM1
2026-08-11
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a regulator of endogenous CUG-exp RNA foci and DMPK mRNA in Myotonic Dystrophy type 1 cells. The study further connects HSP90 activity with p-STAT3 in undifferentiated myoblasts while showing that differentiation reverses the response, emphasizing cell-state-dependent interpretation of RNA-foci assays.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-08-11
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible reagent for studying autophagy pathway modulation and TLR7/9-linked immune signaling in autoimmune disease research. It is appropriate for short-term, water-based workflows, but should not be selected for DMSO- or ethanol-based protocols or long-term storage of prepared solutions.
-
RNASEH1-AS1 in Hepatocellular Carcinoma
2026-08-10
The reference study combines TCGA-based transcriptomic analysis, prognostic modeling, immune-infiltration analysis, and laboratory validation to characterize RNASEH1-AS1 in hepatocellular carcinoma. Its findings support RNASEH1-AS1 as a candidate diagnostic and prognostic biomarker and identify a DKC1-linked stability mechanism, while also highlighting the need for independent clinical validation.
-
CLCC1 and Herpesvirus Nuclear Egress
2026-08-09
The 2024 bioRxiv study identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpesvirus nuclear egress. Its CRISPR-screening and cell-biological evidence connect viral capsid transport with nuclear pore complex insertion, providing a framework for investigating an evolutionarily conserved membrane-remodeling mechanism.
-
Lisinopril Dihydrate in ACE Inhibition Research
2026-08-08
Lisinopril dihydrate supports controlled studies of ACE signaling across hypertension, cardiac injury, and renal disease models. This workflow-focused guide covers preparation, assay design, selectivity controls, and troubleshooting for more reproducible pharmacology.
-
FXR–KLF11 Signaling in Contrast-Induced Kidney Injury
2026-08-07
A 2026 study identifies an FXR–KLF11 transcriptional pathway that suppresses JAK2/STAT3 signaling and reduces contrast-induced acute kidney injury in mouse and renal tubular cell models. Its combination of transcriptomics, promoter validation, cellular perturbation, and FXR genetic deletion provides a mechanistic framework for evaluating CDCA and related FXR agonists in renal injury research.
-
MK-8745: Potent Aurora A Inhibitor for Cancer Research
2026-08-07
MK-8745 is a potent, highly selective Aurora A inhibitor, with sub-nanomolar activity, that enables precise interrogation of mitotic regulation and apoptosis in cancer models. Its robust efficacy in inducing G2/M arrest and apoptosis, particularly in high-risk or chemoresistant tumor cells, makes it a valuable research tool. The compound’s solubility profile and validated in vivo performance further support its translational utility.
-
Sulfo-Cy5 Carboxylic Acid: Benchmarking Fluorescence for Int
2026-08-06
Explore how Sulfo-Cy5 carboxylic acid, a leading fluorescent dye for life sciences, enables advanced, high-sensitivity imaging in intestinal mucosal immunity research. This in-depth analysis bridges dye chemistry, experimental design, and the latest nano-adjuvant breakthroughs for transformative assay outcomes.
-
Pexidartinib (PLX3397): Optimizing CSF1R Inhibition in Cance
2026-08-06
Pexidartinib (PLX3397) enables researchers to dissect CSF1R-driven macrophage biology and modulate tumor microenvironments with precision. This guide delivers actionable protocol enhancements, troubleshooting tips, and translational insights based on the latest neuroimmune findings, spotlighting APExBIO’s reliability.
-
LY2603618: Enhancing Chk1 Inhibition for Cancer Research Pre
2026-08-05
LY2603618 is a highly selective Chk1 inhibitor, enabling precise control of DNA damage response and cell cycle arrest in cancer models. This article details experimental workflows, troubleshooting strategies, and key innovations that position LY2603618 as an indispensable tool for translational oncology and chemotherapy sensitization research.